Det har lanserats en ny benzo med namnet Remimazolam som ska vara som Midazolam men endas funka i 30min sen avtar effekten och tyckte det var så intressant att jag gjorde en tråd här för tror många kan komma att diskutera denna. Så lite info:
Måste bli en jävla kick med så liten halveringstid.
Remimazolam, sold under the brand name Byfavo, is a medication for the induction and maintenance of procedural sedation in adults lasting 30 minutes or less.[2][3][4] is a benzodiazepine derivative drug, developed by PAION, in collaboration with Japanese licensee Ono Pharmaceutical as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures. Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.[5][6]
The most common side effects for procedural sedation include hypotension (low blood pressure), hypertension (high blood pressure), diastolic hypertension, systolic hypertension, hypoxia (low blood oxygen level), and diastolic hypotension.[3][4]
Remimazolam was approved for medical use in the United States in July 2020
Remimazolam is indicated for the induction and maintenance of procedural sedation in adults lasting 30 minutes or less
Måste bli en jävla kick med så liten halveringstid.
Remimazolam, sold under the brand name Byfavo, is a medication for the induction and maintenance of procedural sedation in adults lasting 30 minutes or less.[2][3][4] is a benzodiazepine derivative drug, developed by PAION, in collaboration with Japanese licensee Ono Pharmaceutical as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures. Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.[5][6]
The most common side effects for procedural sedation include hypotension (low blood pressure), hypertension (high blood pressure), diastolic hypertension, systolic hypertension, hypoxia (low blood oxygen level), and diastolic hypotension.[3][4]
Remimazolam was approved for medical use in the United States in July 2020
Remimazolam is indicated for the induction and maintenance of procedural sedation in adults lasting 30 minutes or less